Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group

S P Gampenrieder 1;V Dezentjé 2;M Lambertini 3;A de Nonneville 4;M Marhold 5;F Le Du 6;A Cortés Salgado 7;D Alpuim Costa 8;M Vaz Batista 9;N Chic Ruché 10;C Tinchon 11;A Petzer 12;E Blondeaux 13;L Del Mastro 3;G Targato 14;F Bertucci 4;A Gonçalves 4;F Viret 4;R Bartsch 5;C Mannsbart 5;A Deleuze 6;L Robert 6;C Saavedra Serrano 7;M Gion Cortés 7;M Sampaio-Alves 15;M Vitorino 9;L Pecen 16;C Singer 17;N Harbeck 18;G Rinnerthaler 1;R Greil;Marija Balic;Sonja Heibl;August Felix Zabernigg;Daniel Egle;Margit Sandholzer;Florian Roitner;Johannes Andel;Petra Pichler;Christopher Hager;Michael Knauer;Michael Hubalek;Claudia Bighin;Michelino De Laurentiis;Sabino De Placido;Fabio Puglisi;Luca Boni;Amelie de Gregorio;Tom Degenhardt;Luigi Formisano;Karin Beelen;Timothy Robinson;Amanda Fitzpatrick;Veronique Dieras;Volkmar Muller;Alessandra Gennari;Sabine Linn;Sofia Braga;Javier Cortes;Carlo Palmieri

2023-01-01